stockrowBeam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
Follow BEAM
Alert me
Beam Therapeutics Inc. (BEAM) Debt to equity
Beam Therapeutics Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.1×, up 0.1× from fiscal 2025 (0.0×). Over the past ten years it has ranged from −0.3× (fiscal 2017) to 0.0× (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | −0.3× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 0.1× | 12.14% |
| Jun 2026 | 0.1× | 9.19% |
| Mar 2026 | 0.1× | — |
| Dec 2025 | 0.0× | — |
| 28 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| NAMS NewAmsterdam Pharma Company N.V. compare | 0.0× |
| VRDN Viridian Therapeutics, Inc. compare | 0.0× |
| MBX MBX Biosciences, Inc. compare | 0.0× |
| IDYA IDEAYA Biosciences, Inc. compare | 0.0× |
| XNCR Xencor, Inc. compare | 0.0× |
| BEAM Beam Therapeutics Inc. | 0.1× |
| RCUS Arcus Biosciences, Inc. compare | 0.3× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 0.4× |
| TLX Telix Pharmaceuticals Limited compare | 1.2× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on BEAM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement